Renal cell carcinomas associated with Xp11.2 translocations have recently been identified as a distinct biological entity. The translocation results in the fusion of the transcription factor TFE3 to one of several different fusion partners including PRCC, PSF, NONO, ASPL or CTLC with consecutive overexpression of the chimeric protein. As the true frequency of these neoplasms as well as the biological properties of TFE3 activation in renal cell carcinomas are largely unknown, we have examined TFE3 expression as well as the underlying genetic alterations in a large, hospital-based series of renal cell carcinomas with long-term follow-up information. Out of a total of 876 tumours, TFE3 translocations were detected in five cases (0.6%). Three additional cases were identified in a second series of cases comprising of renal cell carcinomas developing in patients before the age of 50. However, using immunohistochemistry, 9% of all renal cell carcinomas showed some degree of TFE3 reactivity. Interestingly, these cases were associated with high nuclear grade, greater tumour extent and metastatic disease as well as an unfavourable patient outcome on uni-and multivariate analysis. Fluorescence in situ hybridisation (FISH) revealed TFE3 amplifications as an additional, novel mechanism leading to increased TFE3 expression levels. In conclusion, our data show that Xp11 translocation renal cell carcinomas are uncommon tumours accounting for o1% of adult renal cell carcinomas and that the diagnosis of Xp11 translocation renal cell carcinomas needs to be verified using molecular techniques. In turn, TFE3 overexpressing tumours show an aggressive behaviour and Xp11 translocation is only one of several possible underlying genomic alterations.
Renal cell carcinomas associated with Xp11.2 translocations have recently been identified as a biologically distinct entity with characteristic clinical and morphological features. 1 Although these tumours are uncommon in adult patients, they have been shown to comprise B30% of paediatric renal cell carcinomas. 2 At present, five different translocations involving the Xp11.2 chromosomal region have been characterised, resulting in the fusion of the TFE3 (transcription factor binding to IGHM enhancer 3) to PRCC (t(X;1)(p11;q21)), PSF (t(X;1) (p11;p34)), NONO (inv(X)(p11;q12)), ASPL (t(X;17)(p11;q25)) or CLTC (t(X;17)(p11;q23)). [3] [4] [5] [6] In addition, another, at present unknown fusion partner of the TFE3 has recently been located on chromosome 19q13.1.
7
TFE3 belongs to the microphthalmia transcription factor/transcription factor E (MITF-TFE) family, which in addition to microphthalmia-associated transcription factor (MITF) and TFE3 also includes TFEB and TFEC. Under physiological circumstances, MITF is a key regulator in melanocyte development. Gain of function of these genes has been associated with different tumour entities such as malignant melanomas, clear cell sarcoma and renal cell carcinomas. 8, 9 In addition to renal cell carcinomas, translocations of TFE3 have also been identified in alveolar soft part sarcoma and a subset of perivascular epithelioid cell neoplasms (PEComas). 10, 11 The biological behaviour of Xp11 translocation renal cell carcinomas has recently been documented in children and young adults, poor clinical outcome and early metastasis have been reported. [12] [13] [14] To systematically assess the clinical and molecular properties of these tumours, we have examined TFE3 expression as well as the underlying genetic alterations in a large, hospital-based series of renal cell carcinomas with long-term follow-up information. 
Patients and methods

Patients
Tissue-Micro-Arrays
A series of tissue microarrays containing 932 primary tumour and corresponding normal tissue samples of the 932 patients were created as described previously. 15, 16 In total, a set of 19 array blocks was generated, each containing 200 tissue core specimens, representing 50 patients per array. A second TMA containing 104 cases of renal cell carcinomas that had developed in patients before the age of 50 was created. A morphologically representative region was chosen from each of the renal cell carcinomas and two cylindrical core tissue specimens per tumour block measuring 1 mm in diameter were punched from these regions and arrayed into the recipient paraffin block. Of these 104 cases, 57 had already been included in the original arrays described above whereas 47 cases represented new tumours.
Immunohistochemistry
Tissue microarray slides were stained with a polyclonal anti-TFE3 antiserum (final concentration 2 mg/ml; P-16, Santa Cruz Biotechnology, Heidelberg, Germany) as described previously. 17 Nuclear staining intensity was assessed using a three-tiered scoring system. In addition, the absence or presence of cytoplasmic TFE3 expression was noted.
The arrays were independently scored by two experienced pathologists (SMG, SA) blinded to tissue annotations and patient outcomes.
Fluorescence In Situ Hybridization (FISH)
The generation of DNA probes flanking the TFE3 locus (chromosome Xp11.2), a third probe centromeric of ASPL gene (chromosome 17q25.3) and FISH analysis of TFE3 has previously been described in detail. 17 In addition, a commercially available DNA-probe labelling the centromer X (MP Biomedicals Europe, Illkirch, France) was used to assess chromosome X aneuploidy.
Reverse Transcription PCR and Sequence Analyses
RNA extraction and RT-PCR was performed as described previously. 17 Fusion transcripts were detected with the primer combinations summarised in Table 1 followed by direct DNA sequencing using the DYEnamic ET terminator sequencing kit (GE Healthcare) on an ABI prism 377 sequencer (Applied Biosystems, Darmstadt, Germany).
Statistical Methods
Data were analysed using the R software package (version 2.5.1, http://www.rproject.org). For count data, Fisher's exact test (two-sided) was used. The Kaplan-Meier method was applied to calculate survival probabilities for both progression-free and cancer-specific overall survival. For multivariate analysis, the Cox proportional hazards regression model was used. Univariate survival data were tested for significance using the Mantel-Haenszel log rank test. P-values o0.05 were considered significant.
Results
TFE3 Immunohistochemistry
TFE3 immunostains were performed on tissue microarrays containing tumour and corresponding normal renal tissue from 932 patients with renal cell carcinomas. A total of 56 cases were excluded from further analyses either because of insufficient tumour tissue, poor tissue preservation or missing patient information. The clinical and pathological features of the remaining 876 cases are summarised in Table 2 . Median follow-up time was 59 months (mean, 62 months). TFE3 expression was detected in a total of 76 cases (9%). Of these, 26 tumours (3%) showed weak, another 26 (3%) moderate 10 (1%) strong nuclear staining. Cytoplasmic TFE3 staining was detected in 14 tumours (2%), the remaining 800 cases (91%) were completely negative.
TFE3 FISH Analysis and RT-PCR
Tissue for FISH analysis was available in 50 (76%) cases with either nuclear or cytoplasmic TFE3 staining including 9 of the 10 tumours with strong nuclear TFE3 expression. Translocations of TFE3 were found in four cases showing strong nuclear, and one case with cytoplasmatic TFE3 expression, the remaining 45 cases including five tumours with strong nuclear TFE3 reaction did not harbour a TFE3 translocation ( Figure 1 ). To identify the underlying translocation RT-PCR was performed. PCR results and the clinicopathologic characteristics of the five patients with a Xp11 translocation renal cell carcinoma are summarised in Table 3 .
Validation of TFE3 Immunohistochemistry Results
To investigate the frequency of immunhistochemically TFE3 negative Xp11 translocation renal cell carcinomas we constructed a second TMA containing 104 cases of renal cell carcinomas that had developed in patients before the age of 50 as renal cell carcinomas associated with Xp11. 2 translocations have been reported to frequently occur in younger patients. 18 Of these 104 cases (median age at surgery: 39 years, range 4-50 years), 57 had already been included in the original arrays described above whereas 47 cases represented new tumours for which no follow-up information was available. TFE3-FISH analysis was performed on the whole subset, confirming translocations in five cases including two cases that had already been identified in the first series and three new Xp11 translocation renal cell carcinomas (Table 3) . However, TFE3 immunohistochemistry positively labelled a total of 12 renal cell carcinomas, including the five cases with TFE3 translocations as detected by FISH and additional seven tumours without detectable alterations of the TFE3.
TFE3 Amplification
Besides translocation, some tumours showed amplification of TFE3 with between four and eight signals per nucleus (Figure 1 ). In all, 24% of renal cell carcinomas with moderate to strong nuclear expression and no evidence of a TFE3 translocation displayed four or more hybridisation signals, compared with 8% of renal cell carcinomas showing no (Table 4) . Aneuploidy for X-chromosome was detected in four cases with increased TFE3 copy numbers (between four and six signals per nucleus).
Comparison of TFE3 Expression Levels in Non-Xp11 Renal Cell Carcinomas with Clinical and Pathological Features
Univariate analyses showed a significantly poorer cancer-specific survival for tumours with TFE3 expression (Po0.001). This applies for the subset with amplification (Po0.001) and for the subset with unknown underlying pathomechanisms for TFE3 overexpression/expression (Po0.001). For the five adult patients with Xp11 translocation renal cell carcinomas univariate survival analyses did not reach statistical significance possibly because of the low number of patients ( Figure 2 ). In tumours without TFE3 translocations, nuclear or cytoplasmic TFE3 expression was strongly associated with grade of malignancy, tumour extent as well as distant and regional lymph node metastasis (Table 5 ).
To further validate this finding, a multivariate analysis was performed using the Cox proportional hazards model (Table 6 ). The results confirm TFE3 expression as an independent unfavourable 192  168  144  120  96  72  48  24   0  192  168  144  120  96  72  48  24   0  192  168  144  120  96  72  48  24   0  192  168  144  120  96  72 (Table 7) .
Discussion
Contrasting conventional renal cell carcinomas, Xp11.2 translocation associated tumours are not defined on a morphological but solely on a genetic basis. Initially described in children and designated as 'juvenile papillary renal cell carcinoma', there today is increasing evidence that these uncommon neoplasms also occur in adults although their true incidence and clinical peculiarities have not been evaluated in detail. 18, 19 To systematically analyse the role of TFE3 alterations in unselected renal cell carcinomas, we have combined TFE3 immunohistochemistry with molecular analyses of the underlying genomic alterations. In a series of 876 well-characterised renal cell carcinomas, immunohistochemistry revealed that the vast majority (91%) of tumours showed no TFE3 expression at all, whereas the remaining 9% exhibited varying cytoplasmic or nuclear staining patterns. Tissue samples of nine tumours with strong nuclear TFE3 expression, a criterion previously used as an indicator of TFE3 translocations, were available for FISH analyses. 18, 20 Only four out of these nine tumours (44%) harboured a TFE3 translocation. On the other hand, not only these four cases but also all other genetically verified Xp11 translocation renal cell carcinomas from the second TMA series of 104 younger renal cell carcinoma patients showed at least weak nuclear or cytoplasmic positivity. This suggests that immunohistochemistry is a highly sensitive method that may be used as an initial screening tool, but that the diagnosis of Xp11 translocation renal cell carcinomas needs to be genetically verified. As there is evidence of further, as yet unrecognised fusion variants, the direct visualisation of the TFE3 split remains the method with the highest sensitivity for paraffin-embedded, clinical tissue samples. 7, 17, 21 Of the eight genetically verified Xp11 translocation renal cell carcinomas in both series, seven occurred in adult patients corresponding to an overall frequency of 0.75% Xp11-associated tumours in unselected (adult) cases. The average age of patients with Xp11 translocation renal cell carcinomas was 44 years, the oldest patient 75 years at diagnosis. Although some Xp11 translocation renal cell carcinomas already develop in paediatric patients, it appears that the entity in itself is a rare tumour that may occur at any age.
As TFE3 expression in renal cell carcinomas obviously is not limited to Xp11.2 translocations, we further sought to examine its biological properties in usual type renal cell carcinomas (carcinomas with no detectable Xp11 translocation). Nuclear and/or cytoplasmic TFE3 immunoreactivity was detected in a total of 71 (9%) of the 876 tumours. Besides translocations, FISH demonstrated increased TFE3 copy numbers (four to eight signals/ per nucleus) based on gene amplification or aneuploidy in eight immunohistochemically positive tumours. This observation is in line with the previous report of a PEComa containing a TFE3 amplification. 11 However, in 40 tumours neither amplifications nor translocations were detected, suggesting the presence of further genetic or epigenetic alterations leading to TFE3 overexpression. Recently, Hong et al 22 reported TFE3 activation upon inactivation of the tumour suppressor gene FLCN (folliculin). Interestingly, FLCN germline mutations are the genetic background of Birt-HoggDube' syndrome, an uncommon disorder characterized by the development of noncancerous tumours of the hair follicles, lung cysts and renal cell carcinomas. In summary, these data point to the presence of different mechanisms (ie, TFE3 translocation, amplification and FLCN inactivation) that can result in increased TFE3 protein levels in renal cell carcinomas.
Interestingly, renal cell carcinomas with no detectable Xp11 translocation and increased TFE3 expression were significantly associated with unfavourable clinico-pathological features such as higher nuclear grade, advanced tumour stage and the presence of metastatic disease. Especially TFE3-positive non-Xp11 renal cell carcinomas showed a substantially poorer disease-specific overall survival both on univariate and on multivariate analysis. Aggressive clinical behaviour of Xp11 translocation renal cell carcinomas has been reported in previous series and case reports. 13 However, most of these data represent observations in preselected collectives of younger patients. In addition, TFE3-positive tumours without Xp11 translocations typically are not distinguished from true Xp11 translocation renal cell carcinomas. The different genetic alterations leading to TFE3 activation suggest a possible selection by function in renal cell carcinomas, a fact that is further supported by the substantially poorer patient outcome regardless of the underlying mechanism.
As oncogenic TFE3 fusion proteins have been shown to activate MET transcription in vitro, detection of increased TFE3 protein levels in up to 10% of renal cell carcinomas may define a subset of cases with an especially poor prognosis, for which novel MET inhibitors could be of therapeutic value. 23, 24 However, as response to MET inhibitors may depend on the pathomechanism of TFE3 activation, verification of Xp11 translocations could be of additional relevance in this clinical setting.
In conclusion, our data show that TFE3 activation is not limited to renal cell carcinomas associated with Xp11.2 translocations but may also be observed in a subset of usual type renal cell carcinomas characterised by an unfavourable clinical behaviour and poor patient survival. We could identify amplifications of the TFE3 as one novel underlying alteration in some of these cases. However, our findings also indicate that there are further, yet unknown molecular mechanisms leading to TFE3 activation in renal cell carcinomas increased TFE3 protein levels in renal cell carcinomas. Importantly, the increasing molecular insight into the interactions of MIT family transcription factors, such as TFE3 and MET, may point towards a potential therapeutic use of MET inhibition in these uncommon tumours.
